MLi-2

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neuroinflammation Neural Mitochondrial Function Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Amount	10mM/1mL
Item no.	HY-100411-10mM
Targets	LRRK2
CASRN	1627091-47-7
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	MLi-2 is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neurodegeneration
MolecularWeight	379.46
Clinical_Information	No Development Reported
Manufacturers Research_Area	Neurological Disease
Solubility	DMSO : 50 mg/mL (ultrasonic)
Pathway	Autophagy
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100411-10mM-safety-datasheet.pdf